Abbott's FreeStyle Libre 14 day system now available in the U.S. for hospitalized patients with diabetes during COVID-19 Pandemic.

Abbott announced that the FreeStyle Libre 14 day system, the world's leading continuous glucose monitoring (CGM) technology, can now be used in the hospital setting during the COVID-19 pandemic, according to the FDA. This will permit frontline healthcare workers to remotely monitor patients with diabetes receiving inpatient care by assessing real-time glucose levels and glucose history. To help hospitals and medical centers in COVID-19 outbreak hotspots ramp up access to the technology, Abbott will donate 25,000 FreeStyle Libre 14 day sensors in partnership with the American Diabetes Association (ADA), Insulin for Life USA and Diabetes Disaster Response Coalition. According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized. With a one-second scan using a reader or smartphone over the FreeStyle Libre 14 day sensor worn on the back of the upper arm, users get real-time glucose readings every minute, historical trends and patterns, and arrows showing where glucose levels are going without having to fingerstick. At the same time, physicians will receive real-time glucose data and actionable information to help make important treatment decisions through LibreView, a secure, cloud-based diabetes management system. Recent studies showed that users of the FreeStyle Libre 14 day system have improved glucose control, decreased time in hyperglycemia and hypoglycemia as well as reduced hospitalizations, and HbA1C12 levels.